WatchTalking point
Stock has run ahead of the business
Over 5 years the stock returned 18.5% a year while profit shrank 8.1% a year.
Importance 61 / 95 · business vs stock
Aurobindo Pharma · Research view
Aurobindo Pharma Ltd.
NSE: AUROPHARMABSE: 524804ISIN INE406A01037Face value ₹1consolidated
₹1,675
+0.51% · 2026-10-01 · 52-wk ₹1,071–₹1,735
Financials to FY2026 · 8 years of history · prices to 2026-10-01consolidatedstandalone
Section 02 · Synthesis
What stands out?
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
StrengthConcernWatchContext
ContextTalking point
Cheaper than peers — but earns less
P/E of 26.22× is below the pharmaceuticals median (36.26×) — but ROE of 9.9% is also below that peer set (14.4%), so the lower multiple tracks the lower profitability.
Importance 58 / 95 · valuation
WatchTalking point
Volatile earnings
Profit has swung sharply over 7 years (from ₹1,928 to ₹5,334) — one year is a weak guide to the earnings power.
Importance 57 / 95 · growth
StrengthTalking point
Book value compounding
Net worth compounded at 15.4% a year over 7 years (₹13,892 → ₹37,883).
Importance 55 / 95 · financial health
Section 03 · The company
Who is this company?
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
- Market cap
- ₹97,284 cr
- FY2026 revenue
- ₹33,653 cr
- FY2026 net profit
- ₹3,503 cr
- Net worth
- ₹37,883 cr
- Total debt
- ₹7,676 cr
- EPS (basic)
- ₹60.34
- Listed
- NSE · BSE
- Reporting
- Ind-ASApr–Mar
Peer set used on this page: 12 pharmaceuticals.
Section 04 · Business performance
Is the business growing?
RevenueNet profit
Watch
Profit has swung sharply over 7 years (from ₹1,928 to ₹5,334) — one year is a weak guide to the earnings power.
Rule EARNINGS_VOLATILE
- Revenue growth per year
- +8.1%over 7 years
- Revenue growth
- +6.1%vs last year
- Net profit growth
- +0.6%vs last year
- Change in net profit since FY19
- +48%
Revenue has compounded at 8.1% a year over 7 years (₹19,564 → ₹33,653) — steady rather than rapid.
Section 05 · Recent activity
What changed recently?
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Strength
Q1 FY27 net profit was ₹1,032 cr, up 25.2% from ₹824 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Strength
Q1 FY27 revenue was ₹9,150 cr, up 16.3% from ₹7,868 cr in Q1 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Strength
Q1 FY27 EBIT was ₹1,658 cr, up 27.3% from ₹1,303 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
A. Quarterly results
RevenueNet profit
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q2 FY25 | 7,796 | — | 817 | — | 10.5% |
| Q3 FY25 | 7,979 | +8.5% | 846 | −10.0% | 10.6% |
| Q4 FY25 | 8,382 | +10.6% | 903 | −0.5% | 10.8% |
| Q1 FY26 | 7,868 | +4.0% | 824 | −10.2% | 10.5% |
| Q2 FY26 | 8,286 | +6.3% | 848 | +3.8% | 10.2% |
| Q3 FY26 | 8,646 | +8.4% | 910 | +7.6% | 10.5% |
| Q4 FY26 | 8,853 | +5.6% | 921 | +2.0% | 10.4% |
| Q1 FY27 | 9,150 | +16.3% | 1,032 | +25.2% | 11.3% |
B. TTM snapshot
Trailing twelve months to 30 Jun 2026 · sum of the last 4 contiguous quarters
- Revenue
- ₹34,935 crTTM
- EBITDA
- ₹7,775 crTTM
- EBIT
- ₹5,915 crTTM
- PBT
- ₹5,422 crTTM
- Net profit
- ₹3,711 crTTM
C. Corporate actions
17 Apr 2026BuybackBuy Back of Shares
8 Aug 2025DividendInterim Dividend - Rs. - 4.0000 — ₹4.00/share
30 Jul 2024BuybackBuy Back of Shares
20 Feb 2024DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
20 Nov 2023DividendInterim Dividend - Rs. - 3.0000 — ₹3.00/share
17 Feb 2023DividendInterim Dividend - Rs. - 3.0000 — ₹3.00/share
6 Jun 2022DividendInterim Dividend - Rs. - 4.5000 — ₹4.50/share
18 Feb 2022DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
17 Nov 2021DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
27 Aug 2021DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
22 Feb 2021DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
23 Nov 2020DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
21 Aug 2020DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
17 Feb 2020DividendInterim Dividend - Rs. - 1.7500 — ₹1.75/share
21 Nov 2019DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
15 Feb 2019DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
20 Nov 2018DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
20 Feb 2018DividendInterim Dividend - Rs. - 1.0000 — ₹1.00/share
21 Nov 2017DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
8 Jun 2017DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
24 Nov 2016DividendInterim Dividend - Rs. - 1.2500 — ₹1.25/share
9 Jun 2016DividendInterim Dividend - Rs. - 0.7000 — ₹0.70/share
18 Feb 2016DividendInterim Dividend - Rs. - 0.7000 — ₹0.70/share
19 Nov 2015DividendInterim Dividend - Rs. - 0.6000 — ₹0.60/share
21 Aug 2015DividendInterim Dividend - Rs. - 0.5000 — ₹0.50/share
Section 06 · Business performance
Is it becoming more profitable?
EBITDA marginNet margin
Concern
ROE of 9.9% is below the pharmaceuticals median of 14.4%.
Rule ROE_BELOW_PEER_MEDIAN
- EBITDA margin now
- 21.8%
- 8-year range
- 16.1–23.1%
- ROE FY2026
- 9.9%
- ROCE FY2026
- 12.9%
EBITDA margin has ranged from 16.1% to 23.1% over 7 years and sits at 21.8% now.
Section 07 · Financial health
Is financial health improving?
Net worth (shareholders' funds)
Strength
Net worth compounded at 15.4% a year over 7 years (₹13,892 → ₹37,883).
Rule NET_WORTH_COMPOUNDING
Operating cash flowNet profit
- Total debt
- ₹7,676 cr
- Operating cash flow ÷ net profit
- 1.58×FY2026
- Free cash flow
- ₹2,887 cr
- Current ratio
- 1.81×
Section 08 · Relative position
How does it compare with peers?
Ranked against 12 pharmaceuticals (FY2026, consolidated).
Revenue growth
AUROPHARMA · 10th of 12 · set median 14.8%
EBITDA margin
AUROPHARMA · 12th of 12 · set median 28.7%
Return on equity
AUROPHARMA · 11th of 12 · set median 14.4%
P/E ratio
AUROPHARMA · 3rd of 12 · set median 36.3×
Context
P/E of 26.22× is below the pharmaceuticals median (36.26×) — but ROE of 9.9% is also below that peer set (14.4%), so the lower multiple tracks the lower profitability.
Rule CHEAP_VS_LOW_RETURNS
- P / E
- 26.2×TTM to Jun 26
- P / B
- 2.6×latest book
- P / S
- 2.8×TTM sales
- Earnings yield
- 3.8%TTM to Jun 26
On the trailing twelve months. Last full year: P/E 27.8× · P/S 2.8× · ROE 9.9%.
Section 09 · The stock
How has the stock performed?
Watch
Over 5 years the stock returned 18.5% a year while profit shrank 8.1% a year.
Rule STOCK_RAN_AHEAD
- 1-year return
- +54.2%
- 3-year return
- +83.2%
- 5-year return
- +133.5%
- From 52-wk high
- −3.5%
Section 10 · Technical data
What does the technical data say?
Price-action indicators as of 2026-10-01. Secondary to the fundamentals above — included for timing context, not as a signal.
- vs 50-day avg
- Above₹1,644
- vs 200-day avg
- Above₹1,415
- RSI (14)
- 49.9neutral
- MACD histogram
- -5.5
- From 52-wk high
- −3.5%
- From 52-wk low
- +56.4%
- 30-day volatility
- 24.0%ann.
- 6-month return
- +28.4%
Section 11 · Open questions
What should I investigate further?
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
- WatchStock has run ahead of the businessOver 5 years the stock returned 18.5% a year while profit shrank 8.1% a year.STOCK_RAN_AHEAD · conviction 61
- WatchVolatile earningsProfit has swung sharply over 7 years (from ₹1,928 to ₹5,334) — one year is a weak guide to the earnings power.EARNINGS_VOLATILE · conviction 57
- ConcernLess profitable than peersROE of 9.9% is below the pharmaceuticals median of 14.4%.ROE_BELOW_PEER_MEDIAN · conviction 49
- WatchReceivables stretchingReceivable days rose from 66 to 77 — collections are slower.RECEIVABLE_DAYS_JUMP · conviction 42
- Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
Section 12 · Reference
The numbers
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 |
| Total income | 19,679 | 23,185 | 25,155 | 23,776 | 25,146 | 29,559 | 32,346 | 34,145 |
| EBITDA | 4,007 | 4,911 | 5,714 | 4,707 | 4,009 | 6,400 | 7,205 | 7,338 |
| Profit before tax | 3,089 | 3,758 | 7,399 | 3,404 | 2,624 | 4,397 | 5,098 | 5,110 |
| Net profit | 2,365 | 2,830 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 |
| EPS (₹) | 40.4 | 48.3 | 91.0 | 45.2 | 32.9 | 54.2 | 59.8 | 60.3 |
| Net worth | 13,892 | 16,811 | 21,929 | 24,574 | 26,852 | 29,851 | 32,647 | 37,883 |
| Total debt | 6,753 | 5,422 | 4,971 | 2,373 | 4,862 | 6,315 | 7,942 | 7,676 |
| Operating cash flow | — | — | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Free cash flow | — | — | 1,891 | 3,345 | −6 | −286 | 1,960 | 2,887 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 18.1 | 7.3 | -5.3 | 6.0 | 16.7 | 9.4 | 6.1 |
| Profit growth YoY | — | 19.7 | 88.5 | -50.4 | -27.2 | 64.4 | 9.9 | 0.6 |
| Profitability | ||||||||
| EBITDA margin % | 20.5 | 21.3 | 23.1 | 20.1 | 16.1 | 22.1 | 22.7 | 21.8 |
| Net margin % | 12.0 | 12.2 | 21.2 | 11.1 | 7.7 | 10.7 | 10.8 | 10.3 |
| Return on equity % | 17.0 | 18.4 | 27.5 | 11.4 | 7.5 | 11.2 | 11.1 | 9.9 |
| Return on capital % | 16.2 | 18.4 | 19.0 | 13.3 | 9.4 | 14.4 | 14.5 | 12.9 |
| Leverage & cash | ||||||||
| Debt to equity | 0.49 | 0.32 | 0.23 | 0.10 | 0.18 | 0.21 | 0.24 | 0.20 |
| Cash flow ÷ profit | — | — | 0.62 | 1.90 | 1.24 | 0.77 | 1.13 | 1.58 |
| Current ratio | 1.28 | 1.44 | 1.85 | 2.21 | 1.87 | 1.95 | 1.85 | 1.81 |